Literature DB >> 31668701

Evolution and Impact of Subclonal Mutations in Papillary Thyroid Cancer.

Tariq Masoodi1, Abdul K Siraj1, Sarah Siraj1, Saud Azam1, Zeeshan Qadri1, Sandeep K Parvathareddy1, Saif S Al-Sobhi2, Mohammed AlDawish3, Fowzan S Alkuraya4, Khawla S Al-Kuraya5.   

Abstract

Unlike many cancers, the pattern of tumor evolution in papillary thyroid cancer (PTC) and its potential role in relapse have not been elucidated. In this study, multi-region whole-exome sequencing (WES) was performed on early-stage PTC tumors (n = 257 tumor regions) from 79 individuals, including 17 who had developed relapse, to understand the temporal and spatial framework within which subclonal mutations catalyze tumor evolution and its potential clinical relevance. Paired primary-relapse tumor tissues were also available for a subset of individuals. The resulting catalog of variants was analyzed to explore evolutionary histories, define clonal and subclonal events, and assess the relationship between intra-tumor heterogeneity and relapse-free survival. The multi-region WES approach was key in correctly classifying subclonal mutations, 40% of which would have otherwise been erroneously considered clonal. We observed both linear and branching evolution patterns in our PTC cohort. A higher burden of subclonal mutations was significantly associated with increased risk of relapse. We conclude that relapse in PTC, while generally rare, does not follow a predictable evolutionary path and that subclonal mutation burden may serve as a prognostic factor. Larger studies utilizing multi-region sequencing in relapsed PTC case subjects with matching primary tissues are needed to confirm these observations.
Copyright © 2019 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  evolution; exome sequencing; multi-tissue; papillary thyroid cancer; phylogeny; recurrence; subclonal mutations

Mesh:

Year:  2019        PMID: 31668701      PMCID: PMC6849094          DOI: 10.1016/j.ajhg.2019.09.026

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  67 in total

1.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.

Authors:  Ronglai Shen; Venkatraman E Seshan
Journal:  Nucleic Acids Res       Date:  2016-06-07       Impact factor: 16.971

2.  Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.

Authors:  Ali S Alzahrani; Avaniyapuram Kannan Murugan; Ebtesam Qasem; Meshael M Alswailem; Balgees AlGhamdi; Yosra Moria; Hindi Al-Hindi
Journal:  Endocrine       Date:  2018-09-29       Impact factor: 3.633

Review 3.  Biological and therapeutic impact of intratumor heterogeneity in cancer evolution.

Authors:  Nicholas McGranahan; Charles Swanton
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

4.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

5.  The Profile of Genetic Mutations in Papillary Thyroid Cancer Detected by Whole Exome Sequencing.

Authors:  Yi Fang; Xiao Ma; Jing Zeng; Yanwen Jin; Yong Hu; Jinjing Wang; Ran Liu; Cheng Cao
Journal:  Cell Physiol Biochem       Date:  2018-10-02

Review 6.  Systematic Review of Trends in the Incidence Rates of Thyroid Cancer.

Authors:  Joseph J Wiltshire; Thomas M Drake; Lesley Uttley; Sabapathy P Balasubramanian
Journal:  Thyroid       Date:  2016-11       Impact factor: 6.568

7.  Long-term results in elderly patients with differentiated thyroid carcinoma.

Authors:  Louiza Vini; Stephen L Hyer; Jennifer Marshall; Roger A'Hern; Clive Harmer
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

8.  Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.

Authors:  Bryan R Haugen; Daniel W Bowles; Nikita Pozdeyev; Laurie M Gay; Ethan S Sokol; Ryan Hartmaier; Kelsi E Deaver; Stephanie Davis; Jena D French; Pierre Vanden Borre; Daniel V LaBarbera; Aik-Choon Tan; Rebecca E Schweppe; Lauren Fishbein; Jeffrey S Ross
Journal:  Clin Cancer Res       Date:  2018-04-03       Impact factor: 12.531

Review 9.  The multistep nature of cancer.

Authors:  B Vogelstein; K W Kinzler
Journal:  Trends Genet       Date:  1993-04       Impact factor: 11.639

10.  Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.

Authors:  Ali S Alzahrani; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2013-01-21       Impact factor: 5.678

View more
  7 in total

1.  Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.

Authors:  Julia Schiantarelli; Theodora Pappa; Jake Conway; Jett Crowdis; Brendan Reardon; Felix Dietlein; Julian Huang; Darren Stanizzi; Evan Carey; Alice Bosma-Moody; Alma Imamovic; Seunghun Han; Sabrina Camp; Eric Kofman; Erin Shannon; Justine A Barletta; Meng Xiao He; David Liu; Jihye Park; Jochen H Lorch; Eliezer M Van Allen
Journal:  JCO Precis Oncol       Date:  2022-08

2.  Gene Mutation Analysis in Papillary Thyroid Carcinoma Using a Multi-Gene Panel in China.

Authors:  Qiang Wang; Ning Zhao; Jun Zhang
Journal:  Int J Gen Med       Date:  2021-09-02

3.  Intratumor Heterogeneity as a Prognostic Factor in Solid Tumors: A Systematic Review and Meta-Analysis.

Authors:  Tao Yu; Xin Gao; Zicheng Zheng; Xinyu Zhao; Shiyao Zhang; Chunqiang Li; Gang Liu
Journal:  Front Oncol       Date:  2021-10-15       Impact factor: 6.244

4.  Genetic and Clinicopathologic Characteristics of Papillary Thyroid Carcinoma in the Chinese Population: High BRAF Mutation Allele Frequency, Multiple Driver Gene Mutations, and RET Fusion May Indicate More Advanced TN Stage.

Authors:  Zhihong Wang; Peng Tang; Surong Hua; Junyi Gao; Bin Zhang; Hua Wan; Qixi Wu; Jiaxin Zhang; Ge Chen
Journal:  Onco Targets Ther       Date:  2022-02-09       Impact factor: 4.147

5.  Novel Genomic Roadmaps and Their Clinical Translation Ahead.

Authors:  Erik K Alexander
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 5.958

Review 6.  Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications.

Authors:  Valerie Jacquemin; Mathieu Antoine; Geneviève Dom; Vincent Detours; Carine Maenhaut; Jacques E Dumont
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

7.  APOBEC SBS13 Mutational Signature-A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma.

Authors:  Sarah Siraj; Tariq Masoodi; Abdul K Siraj; Saud Azam; Zeeshan Qadri; Sandeep K Parvathareddy; Rong Bu; Khawar S Siddiqui; Saif S Al-Sobhi; Mohammed AlDawish; Khawla S Al-Kuraya
Journal:  Cancers (Basel)       Date:  2022-03-21       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.